During the last three months, 8 analysts shared their evaluations of Intra-Cellular Therapies (NASDAQ:ITCI), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback